Position of the Transparency Council – Remsima (infliximab)

At its meeting on 24 February 2025, the Transparency Council adopted position No. 28/2025 on the evaluation of the drug Remsima (infliximab) within the framework of the drug program B.55. “Treatment of patients with ulcerative colitis (UC) (ICD-10 K51)”

Publication of the position >>